Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia.
Mandell
Lionel A
LA
McMaster University, Hamilton, Ontario, Canada. lmandell@mcmaster.ca
Jones
Ronald N
RN
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D024841:Fluoroquinolones; D005500:Follow-Up Studies; D000077734:Gatifloxacin; D006801:Humans; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D018570:Risk Assessment; D012449:Safety; D016896:Treatment Outcome; D014481:United States
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D000077734:Gatifloxacin